Femasys Inc. (FEMY)
| Market Cap | 4.93M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | -11.72M |
| Shares Out | 15.91M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,537 |
| Open | 0.304 |
| Previous Close | 0.306 |
| Day's Range | 0.300 - 0.310 |
| 52-Week Range | 0.248 - 1.787 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+2,319.36%) |
| Earnings Date | Nov 9, 2023 |
About FEMY
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially w... [Read more]
Financial Performance
In 2022, Femasys's revenue was $1.21 million, an increase of 2.25% compared to the previous year's $1.18 million. Losses were -$11.39 million, 51.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FEMY stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 2,319.36% from the latest price.
News
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, access...
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
ATLANTA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidat...
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc ®
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial - - First of its kind, non-surgical, permanent birth control option begins enrollment in landmark ...
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
FemBloc® patent application provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc® patent application provides additional coverage for Femasys'...
Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada
-- FemCath ® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is used in conjunction with Femasys' FemVu...
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally...
Femasys' FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
- FemCerv ® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity -
Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
ATLANTA, May 01, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally...
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ATLANTA, April 19, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimal...
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys' FemBloc ® for permanent birt...
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline diagn...
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
--FemCerv ® , the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the AAGL conference attended by over 2,000 leading gynec...
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility-- --FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male f...
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i...
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
--FemaSeed ® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- -- Company remains on track to file an Investigational Device Exemption (IDE)...
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
- Updated FemaSeed ® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal of achieving accelerated enrollment -
Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress
ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i...
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory agencies and guidance in the total product lifecycle of medical devices Accompli...
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
Company remains on track to file an investigational device exemption (IDE) for a pivotal trial to support a pre-market authorization (PMA) in the first quarter of 2023 Company remains on track to file...
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
- FemCerv ® is the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care -
Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ATLANTA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally ...
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i...
Femasys to Participate in the Women's Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET
ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i...
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022
- Furthers advancement of much-needed minimally invasive technologies for underserved areas of women's health with pending commercialization of products, FemCerv ® and FemCath ™ expected by year-end